# Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

> **NCT07549906** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 45 (estimated)

## Conditions studied

- Colon Cancer (Stage II &Amp; III)
- Immunotherapy
- Beta Blocker
- Neoadjuvant Chemoimmunotherapy

## Interventions

- **DRUG:** Iparomlimab/Tuvonralimab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Propranolol

## Key facts

- **NCT ID:** NCT07549906
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549906, "Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07549906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*